In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cance… (NCT06827639) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
France640 participantsStarted 2025-04-30
Plain-language summary
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 years of age or older
* Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications
* Written informed consent signed from subject prior to performing any protocol-related procedures
Exclusion Criteria:
* Use of any investigational agent within 14 days prior first visit;
* Patient under guardianship/trusteeship or legally incapacitated person;
* Patient unable to understand read and/or sign an informed consent;
* Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;
* Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme;
* Patients who are known to be HIV positive
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Identification of circulating and infiltrating tumor cells .
Timeframe: From screening to end of study at 8 weeks